Kane Biotech Inc.
KNE.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -72.63% | 141.30% | 1,344.70% | 1,281.40% | 210.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.63% | 141.30% | 1,344.70% | 1,281.40% | 210.74% |
| Cost of Revenue | -36.66% | 354.50% | 3,358.41% | 2,919.86% | 218.03% |
| Gross Profit | -109.52% | 2.44% | 612.46% | 690.86% | 204.15% |
| SG&A Expenses | -52.49% | -30.74% | 21.12% | 26.29% | 291.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.27% | -13.10% | 55.82% | 63.76% | 630.07% |
| Operating Income | 35.02% | 38.80% | 2.44% | -9.64% | -56.49% |
| Income Before Tax | 35.92% | 41.33% | 17.84% | 3.25% | -23.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.82% | 64.48% | 43.40% | 30.96% | -23.19% |
| Earnings from Discontinued Operations | -112.16% | -111.70% | 3,258.52% | 2,042.75% | 2,611.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.72% | -166.27% | 220.19% | 219.94% | 231.00% |
| EBIT | 35.02% | 38.80% | 2.44% | -9.64% | -56.49% |
| EBITDA | 36.98% | 39.39% | 1.30% | -10.66% | -57.98% |
| EPS Basic | -145.48% | -161.15% | 221.33% | 217.12% | 227.05% |
| Normalized Basic EPS | 52.35% | 51.03% | 28.25% | 12.12% | -20.57% |
| EPS Diluted | -181.98% | -223.75% | 167.87% | 162.77% | 162.09% |
| Normalized Diluted EPS | 50.92% | 49.73% | 31.03% | 14.81% | -18.12% |
| Average Basic Shares Outstanding | 46.35% | 13.66% | 9.35% | 7.27% | 8.54% |
| Average Diluted Shares Outstanding | 42.80% | 11.53% | 9.83% | 7.84% | 9.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |